FDA Prioritizes Review of PADCEV and Keytruda Treatment for Bladder Cancer Patients Without Cisplatin Eligibility

FDA Grants Priority Review to PADCEV™ + Keytruda® for Bladder Cancer

In an important development for bladder cancer treatment, the U.S. Food and Drug Administration (FDA) has granted priority review for a supplemental Biologics License Application (sBLA) from Astellas Pharma and Pfizer. This sBLA seeks to expand the indication of PADCEV™ (enfortumab vedotin-ejfv) combined with Keytruda® (pembrolizumab) as a perioperative treatment for muscle-invasive bladder cancer (MIBC) patients, regardless of their eligibility for cisplatin treatment. This would be a pioneering step forward, as it would become the first treatment regimen applicable to all patients with MIBC during the critical perioperative phase.

Background and Significance

The approval of PADCEV in combination with Keytruda was previously established for patients unable to tolerate cisplatin, but now the new filing taps into providing therapy for a broader patient demographic. Muscle-invasive bladder cancer can lead to a staggering recurrence rate of over 50% even post-surgery. By addressing treatment strategies beforehand and post-surgery, the sBLA aims to significantly enhance patient outcomes. Astellas’s Head of Oncology Development, Dr. Moitreyee Chatterjee-Kishore, emphasized that the clinical data from the EV-304 trial showcases how this combination could mitigate the risk of recurrence and significantly uplift patients’ quality of life.

Clinical Trial Data Insights

The pivotal sBLA submission was founded on results from the Phase 3 EV-304 clinical trial, which explored the effectiveness of perioperative enfortumab vedotin in conjunction with pembrolizumab. The findings were compelling; they showed a 47% decrease in tumor recurrence, progression, or mortality while also achieving a 35% reduction in the likelihood of death compared to standard cisplatin-based chemotherapy protocols. Moreover, the trial produced a remarkable pathological complete response (pCR) rate of nearly 56%, significantly more than the 32.5% observed in the chemotherapy segment of the study.

Regulatory Outlook

The FDA, under the Prescription Drug User Fee Act (PDUFA), has a targeted decision date set for August 17, 2026, indicating a strong commitment to potentially fast-tracking this crucial treatment option. The regulatory outlook comes as both Astellas and Pfizer, notable players in the oncology space, eagerly prepare to broaden the scope of their therapeutic offerings. This not only represents an opportunity to alter treatment paths for patients newly diagnosed with MIBC but also opens doors to addressing unmet needs among various demographics within this patient population.

Ongoing Challenges

Nevertheless, challenges linger for bladder cancer patients. Surgery often marks the first step in a grueling journey; many patients face an uncertain future as recurrence of cancer remains common. If sanctioned, the combination of PADCEV and pembrolizumab could profoundly change the narrative, potentially leading to a new standard of care in treating MIBC.

About PADCEV and Keytruda

PADCEV is an antibody-drug conjugate designed to target Nectin-4, a protein prevalent on bladder cancer cells. Keytruda is a PD-1 inhibitor known for its function in harnessing the body’s immune system against cancer. Both drugs have garnered attention for their roles in addressing advanced forms of bladder and other cancers, showcasing a partnership that could redefine expectations in survival and quality of life for patients.

Global Context

Globally, bladder cancer is the ninth most commonly diagnosed cancer, affecting over 600,000 individuals annually. In the U.S. alone, around 85,000 new cases are identified yearly. Consequently, the urgency for effective, innovative treatments continues to escalate. The successful implementation of PADCEV and Keytruda could turn out to be a significant milestone in this ongoing battle against bladder cancer.

As Astellas and Pfizer await the FDA's determination, the oncological community watches closely, hopeful for a breakthrough that may finally empower patients and reshape the landscape of treatment for muscle-invasive bladder cancer. This initiative marks a promising phase in cancer treatment evolution, poised to bring real change in patient care strategies across the board.